What is fibrolamellar hepatocellular carcinoma?

Fibrolamellar hepatocellular carcinoma (FHCC) is a type of cancer that occurs in the liver. It is a relatively rare tumor that mainly affects people under 40 years of age. Symptoms of this type of cancer are not always obvious, and may generally feel good, weight loss and abdominal pain. Fibrolamellar hepatocellular carcinoma is associated with a better view than the most common type of liver cancer, known as hepatocellular carcinoma. This type of neoplasia digestive system can be detected as a swelling in the abdomen that the doctor may feel. Swelling develops as a result of the liver enlargement as a result of a developing tumor. While more common liver cancer, hepatocellular carcinoma, it is usually associated with the form of liver damage called cirrhosis, cirrhosis is not usually observed in the liver of the peopla with fibrolamellar hepatocellular carcinoma.

The most common type of treatment includes surgery to remove a part or all liver. If the surgeon believes that the entire tumor can be removedCutting only a part of the liver, it will be done. Where too much liver is accepted to make it feasible, the entire organ can be eliminated and replaced by a donor liver. This depends on the available donor body.

Less common treatment that can be used in patients whose tumors have spread to other parts of the body is chemotherapy. Chemotherapy includes the use of a number of doses of one or a combination of drugs, often administered by dripping by feeding into a vein. After surgery, chemotherapy can also be administered to remove fibrolamellar hepatocellular carcinoma. It is to kill Any cancer cells that could be left after surgery.

Statistics on fibrolamellar forecast of hepatocellular cancer show that about a third of patients are still alive five years after the diagnosis of their cancer. This is much better than a view of hepatocellular carcinoma where it isn about a quarter of patients will survive a year after diagnosis. Doctors are not sure whether the difference in prognosis could exist, because patients with fibrolamellary hepatocellular carcinoma are generally younger and healthier, just like their liver usually do not have cirrhosis.